Critical Path Paved With Fewer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Deputy Commissioner Gottlieb says that the agency's innovation initiative will produce smaller trial requirements stemming from a better understanding of drug mechanics.